Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Market Analysis & Valuation

UpdatedAug 23, 2026
DataAggregated Company Financials
Companies7727
  • 7D-1.5%
  • 3M2.4%
  • 1Y17.8%
  • YTD10.5%

Over the last 7 days, the market has dropped 1.5%, driven by a loss of 3.5% in the Information Technology sector. Meanwhile, the Healthcare sector has outperformed, gaining 4.2% in that time. In the last year, the market is actually up 18%. Earnings are forecast to grow by 17% annually.

Trending IndustriesOil and GasGoldBiotechSoftwareRenewable Energy

Market Valuation and Performance

Has the U.S. Market valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 23 Aug 2026US$77.0tUS$25.1tUS$2.7t19.1x28.3x3.1x
Tue, 21 Jul 2026US$79.6tUS$24.4tUS$2.5t19.2x31.7x3.3x
Thu, 18 Jun 2026US$81.5tUS$24.3tUS$2.5t18.7x33.1x3.4x
Sat, 16 May 2026US$73.3tUS$24.2tUS$2.4t18.4x30.3x3x
Mon, 13 Apr 2026US$71.5tUS$23.7tUS$2.3t19.2x31x3x
Wed, 11 Mar 2026US$71.3tUS$23.7tUS$2.3t18.7x31x3x
Fri, 06 Feb 2026US$72.1tUS$23.5tUS$2.3t19.3x31.2x3.1x
Sun, 04 Jan 2026US$71.9tUS$23.2tUS$2.3t19x31.4x3.1x
Tue, 02 Dec 2025US$71.7tUS$23.1tUS$2.3t18.6x31.5x3.1x
Thu, 30 Oct 2025US$67.7tUS$22.8tUS$2.3t18.5x30.1x3x
Sat, 27 Sep 2025US$69.7tUS$22.9tUS$2.2t19.2x31.9x3x
Mon, 25 Aug 2025US$67.9tUS$23.0tUS$2.2t19.3x31.4x2.9x
Wed, 23 Jul 2025US$65.8tUS$22.5tUS$2.1t18.8x31.2x2.9x
Fri, 20 Jun 2025US$62.5tUS$22.5tUS$2.1t17.7x29.8x2.8x
Sun, 18 May 2025US$62.2tUS$22.4tUS$2.1t18.1x29.7x2.8x
Tue, 15 Apr 2025US$55.4tUS$21.9tUS$2.1t16.4x26.9x2.5x
Thu, 13 Mar 2025US$58.1tUS$21.9tUS$2.1t17.2x28.3x2.6x
Sat, 08 Feb 2025US$64.1tUS$21.8tUS$2.0t18.5x31.4x2.9x
Mon, 06 Jan 2025US$62.5tUS$22.0tUS$1.9t18.4x32.3x2.8x
Wed, 04 Dec 2024US$63.8tUS$22.0tUS$1.9t19.5x33.1x2.9x
Fri, 01 Nov 2024US$59.4tUS$21.8tUS$1.9t18x31.6x2.7x
Sun, 29 Sep 2024US$59.6tUS$21.7tUS$1.9t18.3x31.8x2.7x
Tue, 27 Aug 2024US$58.3tUS$21.5tUS$1.8t18.2x31.6x2.7x
Thu, 25 Jul 2024US$57.8tUS$21.4tUS$1.8t17.7x31.4x2.7x
Sat, 22 Jun 2024US$56.5tUS$21.3tUS$1.8t16.6x30.8x2.7x
Mon, 20 May 2024US$55.2tUS$21.2tUS$1.8t17.5x30.5x2.6x
Wed, 17 Apr 2024US$52.5tUS$21.1tUS$1.8t16.4x28.4x2.5x
Fri, 15 Mar 2024US$53.8tUS$21.1tUS$1.8t16.4x29.2x2.6x
Sun, 11 Feb 2024US$52.3tUS$21.0tUS$1.8t16.3x29.3x2.5x
Tue, 09 Jan 2024US$49.4tUS$21.0tUS$1.8t16.8x28.1x2.3x
Thu, 07 Dec 2023US$47.6tUS$21.0tUS$1.8t16.1x27.2x2.3x
Sat, 04 Nov 2023US$45.6tUS$21.0tUS$1.7t15.4x26.5x2.2x
Mon, 02 Oct 2023US$45.3tUS$21.0tUS$1.7t15.4x26.4x2.2x
Wed, 30 Aug 2023US$47.4tUS$20.9tUS$1.7t15.8x27.6x2.3x
Price to Earnings Ratio

27.6x


Total Market Cap: US$47.4tTotal Earnings: US$1.7tTotal Revenue: US$20.9tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Market Price to Earnings3Y Average 30.2x202420252026
Current Market PE
  • Investors are relatively neutral on the American market at the moment, indicating that they expect earnings will grow in line with historical growth rates.
  • The market is trading close to its 3-year average PE ratio of 30.2x.
Past Earnings Growth
  • The earnings for American listed companies have grown 17% per year over the last three years.
  • Revenues for these companies have grown 6.2% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Sector Trends

Which sectors have driven the changes within the U.S. Market?

US Market-1.49%
Materials4.41%
Healthcare4.20%
Energy2.10%
Consumer Discretionary0.023%
Real Estate-0.16%
Financials-1.21%
Telecom-1.58%
Consumer Staples-1.80%
Tech-3.51%
Utilities-3.62%
Industrials-3.79%
Sector PE
  • Investors favour the Healthcare sector the most for future growth, which is trading close to its 3-year average PE ratio of 65.5x.
    • The market's confidence is likely because analysts are expecting annual earnings growth of 20.4%, which is higher than its past year's earnings growth of 17.4% per year.
  • The Financials sector is the least preferred by investors for future growth, which is trading close to its 3-year average of 17.5x.
Forecasted Growth
  • Analysts are most optimistic on the Tech sector, expecting annual earnings growth of 23% over the next 5 years.
  • This is roughly in line with its past earnings growth rate.
  • In contrast, the Energy sector is expected to see its earnings grow by 6.1% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuationSector
TSLA TeslaUS$362.866.0%
+US$81.3b		6.7%PE376.5xConsumer Discretionary
LLY Eli LillyUS$1.26k6.4%
+US$67.1b		76.4%PE41.9xHealthcare
AAPL AppleUS$309.351.1%
+US$49.9b		35.8%PE35xTech
MRK MerckUS$152.5512.3%
+US$41.2b		74.6%PE118.6xHealthcare
MRNA ModernaUS$145.13129.2%
+US$32.7b		435.1%PS26xHealthcare
See more

Market Insights

Header cover image
Every new payment app was supposed to kill Visa and Mastercard. Instead, they got bigger. So what does that mean for the payment stocks on your radar?
Continue reading
Picking portfolio winners takes more than hot air

Latest News

WMT
US$103.70
Walmart
7D
-10.0%
1Y
7.1%
Analysis Article • 5h

Walmart Inc. Just Beat EPS By 7.7%: Here's What Analysts Think Will Happen Next

It's been a sad week for Walmart Inc. ( NASDAQ:WMT ), who've watched their investment drop 10% to US$104 in the week...
NVDA
US$214.72
NVIDIA
7D
-4.6%
1Y
20.6%
Seeking Alpha • 8h

Nvidia Stock May Plunge After Earnings, Even If It Beats

Summary Nvidia faces elevated expectations ahead of earnings, with the market pricing in strong growth and a high bar for outperformance. Options and technical analysis indicate asymmetric post-earnings risk, with limited upside and potential for a sharp decline to $190 support. Positive gamma positioning may cap NVDA’s upside while slowing initial declines, but a break below $210 could accelerate downside volatility. Despite a history of beating estimates, NVDA’s post-earnings moves often remain within options-implied ranges, limiting outsized gains. Read the full article on Seeking Alpha
ABBV
US$264.96
AbbVie
7D
6.2%
1Y
25.8%
AMZN
US$258.63
Amazon.com
7D
-1.5%
1Y
13.0%
JNJ
US$270.24
Johnson & Johnson
7D
3.8%
1Y
50.7%
Seeking Alpha • 17h

Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push

Summary Johnson & Johnson (JNJ) maintains a 'Buy' rating, driven by robust Q2 2026 sales growth and pipeline advancements. JNJ's top-performing drugs, DARZALEX and TREMFYA, fueled a 6.6% revenue increase to $25.3 billion, prompting raised full-year 2026 guidance. CAPLYTA's label expansion for schizophrenia relapse prevention and IMAAVY's potential first-mover status in wAIHA represent major growth catalysts. Risks include uncertain sustainability of high sales growth rates and regulatory outcomes for key pipeline assets. Read the full article on Seeking Alpha
META
US$549.90
Meta Platforms
7D
-6.8%
1Y
-27.1%
MSFT
US$483.24
Microsoft
7D
-2.5%
1Y
-4.7%
TSLA
US$362.86
Tesla
7D
6.0%
1Y
6.7%
MRK
US$152.55
Merck
7D
12.3%
1Y
74.6%
AAPL
US$309.35
Apple
7D
1.1%
1Y
35.8%
LLY
US$1,255.40
Eli Lilly
7D
6.4%
1Y
76.4%
Narrative Update • Aug 22

LLY: Obesity Franchise Concentration And Pricing Pressure Will Constrain Future Upside

Analysts have lifted the Eli Lilly fair value estimate from $899.73 to $982.09. Higher price targets reflect confidence that strong incretin demand, obesity franchise momentum and updated long-term guidance support a slightly higher assumed future P/E and profit margin, even with a modestly higher discount rate and tempered revenue growth inputs.
SCCO
US$216.00
Southern Copper
7D
17.0%
1Y
130.2%
MRNA
US$145.13
Moderna
7D
129.2%
1Y
435.1%
AMD
US$473.25
Advanced Micro Devices
7D
-8.0%
1Y
182.1%
AVGO
US$368.45
Broadcom
7D
-6.2%
1Y
25.3%
Seeking Alpha • Aug 20

Broadcom: Marvell Panic Causes A Huge Buying Opportunity

Summary Broadcom Inc. remains a prime beneficiary of the AI boom, with robust profit growth expected for years. The recent selloff following the Marvell-Alphabet deal is seen as an overreaction; the partnership does not threaten AVGO’s position or growth trajectory. AVGO’s valuation is compelling, with downside risk already priced in even under conservative growth assumptions. Even with bearish growth scenarios, AVGO offers attractive annualized returns of 12%+, with potential for much higher upside if consensus is met or exceeded. Read the full article on Seeking Alpha
INTC
US$90.07
Intel
7D
-12.1%
1Y
263.2%
Seeking Alpha • Aug 20

Intel: Why I Am Not Buying The Dip

Summary Intel delivered impressive second-quarter revenue growth of 25% year-over-year alongside strong gross margin expansion and doubled consensus EPS estimates today. Data Center and AI momentum surged 59% annually, benefiting from server CPU demand, higher average selling prices, and 40% margins. Shareholder dilution from pricing 210.5 million new shares, elevated capital expenditures, and ongoing foundry operating losses create near-term fundamental headwinds. Long-term structural catalysts include Intel 14A foundry customer adoption, Tesla partnerships, EMIB advanced packaging scaling, and expanding agentic CPU demand. Extreme valuation multiples compared to semiconductor peers make execution risks asymmetric, warranting a Hold rating until shares pull back significantly. Read the full article on Seeking Alpha